BidaskClub Downgrades Supernus Pharmaceuticals, Inc. (SUPN) to Hold
BidaskClub downgraded shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from a buy rating to a hold rating in a research report report published on Wednesday morning.
SUPN has been the topic of several other reports. Janney Montgomery Scott began coverage on Supernus Pharmaceuticals in a research report on Friday, July 14th. They issued a neutral rating and a $47.00 price target on the stock. Stifel Nicolaus reaffirmed a buy rating and issued a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Piper Jaffray Companies downgraded Supernus Pharmaceuticals from an overweight rating to a neutral rating and set a $46.00 price target on the stock. in a research report on Monday, July 17th. Jefferies Group LLC set a $35.00 price target on Supernus Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, May 10th. Finally, Zacks Investment Research raised Supernus Pharmaceuticals from a hold rating to a buy rating and set a $49.00 price target on the stock in a research report on Thursday, July 13th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $48.43.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded down 1.56% during midday trading on Wednesday, hitting $41.05. The stock had a trading volume of 661,571 shares. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 20.72 and a beta of 1.31. The firm has a 50-day moving average price of $42.27 and a 200-day moving average price of $33.33. Supernus Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $44.95.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The company had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. On average, equities analysts anticipate that Supernus Pharmaceuticals will post $1.00 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Supernus Pharmaceuticals, Inc. (SUPN) to Hold” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/05/bidaskclub-downgrades-supernus-pharmaceuticals-inc-supn-to-hold.html.
In other news, VP Padmanabh P. Bhatt sold 2,556 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $44.90, for a total value of $114,764.40. Following the completion of the transaction, the vice president now owns 24,944 shares in the company, valued at $1,119,985.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the transaction, the vice president now owns 37,500 shares of the company’s stock, valued at approximately $1,346,250. The disclosure for this sale can be found here. Insiders sold 24,291 shares of company stock valued at $962,766 in the last quarter. 6.70% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its position in Supernus Pharmaceuticals by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,107,007 shares of the specialty pharmaceutical company’s stock worth $27,952,000 after buying an additional 51,511 shares during the period. Creative Planning boosted its position in Supernus Pharmaceuticals by 251.8% in the first quarter. Creative Planning now owns 10,905 shares of the specialty pharmaceutical company’s stock worth $341,000 after buying an additional 7,805 shares during the period. Campbell Newman Asset Management Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter worth about $267,000. Juncture Wealth Strategies LLC boosted its position in Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after buying an additional 433 shares during the period. Finally, Louisiana State Employees Retirement System boosted its position in Supernus Pharmaceuticals by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 20,400 shares of the specialty pharmaceutical company’s stock worth $639,000 after buying an additional 500 shares during the period. Institutional investors own 91.23% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.